Neurocrine Biosciences NBIX Collaboration revenues — Total revenues
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Neurocrine Biosciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Neurocrine Biosciences's collaboration revenues — total revenues.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neurocrine Biosciences's collaboration revenues — total revenues?
- Neurocrine Biosciences (NBIX) reported collaboration revenues — total revenues of $3.5M in Q1 2026.
- How has Neurocrine Biosciences's collaboration revenues — total revenues changed year-over-year?
- Neurocrine Biosciences's collaboration revenues — total revenues decreased by 60.7% year-over-year, from $8.9M to $3.5M.
- What is the long-term trend for Neurocrine Biosciences's collaboration revenues — total revenues?
- Over 4 years (2021 to 2025), Neurocrine Biosciences's collaboration revenues — total revenues has grown at a -11.5% compound annual growth rate (CAGR), from $43.4M to $26.6M.
- What does collaboration revenues — total revenues mean?
- Collaboration revenues represent income generated through strategic partnerships, licensing agreements, and joint development arrangements with other pharmaceutical or biotechnology entities. These revenues typically include upfront payments, milestone payments, and royalties derived from the commercialization of drug candidates developed in conjunction with partners. This metric serves as a key indicator of the company's ability to monetize its research pipeline and leverage external expertise to accelerate drug development.